Royalty Pharma plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RPRX research report →
Companywww.royaltypharma.com
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- CEO
- Pablo Legorreta
- IPO
- 2020
- Employees
- 75
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $22.87B
- P/E
- 27.73
- P/S
- 9.36
- P/B
- 3.33
- EV/EBITDA
- 17.65
- Div Yield
- 1.71%
Profitability
- Gross Margin
- 99.95%
- Op Margin
- 67.93%
- Net Margin
- 33.91%
- ROE
- 12.67%
- ROIC
- 8.43%
Growth & Income
- Revenue
- $2.38B · 5.06%
- Net Income
- $770.95M · -10.25%
- EPS
- $2.33 · 21.35%
- Op Income
- $1.56B
- FCF YoY
- -10.08%
Performance & Tape
- 52W High
- $53.47
- 52W Low
- $32.15
- 50D MA
- $48.68
- 200D MA
- $41.46
- Beta
- 0.40
- Avg Volume
- 3.36M
Get TickerSpark's AI analysis on RPRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Urist Marshall | sell | 13,684 |
| May 14, 26 | Norden Gregory | sell | 3,045 |
| May 6, 26 | Legorreta Pablo G. | other | 143,821 |
| May 6, 26 | Coyne Terrance P. | other | 24,263 |
| May 6, 26 | Hite Christopher | other | 24,263 |
| May 6, 26 | Urist Marshall | other | 18,197 |
| Apr 28, 26 | Coyne Terrance P. | sell | 1,875 |
| Apr 28, 26 | Coyne Terrance P. | sell | 32,916 |
| Apr 1, 26 | Coyne Terrance P. | sell | 1,875 |
| Apr 1, 26 | Coyne Terrance P. | sell | 32,916 |
Our RPRX Coverage
We haven't published any research on RPRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RPRX Report →